Hypothesis\n\nIntermittent pulses of β‑hydroxybutyrate (BHB) driven by exogenous ketone esters create a rhythmic inhibition of class I HDACs that entrains circadian chromatin remodeling, thereby amplifying FOXO3‑dependent antioxidant gene expression while preventing the chronic HDAC suppression that triggers senescence in heart and kidney.\n\n## Rationale\n\n- Preclinical data show BHB extends median lifespan 21% in mice and delays senescence via HDAC1/2/3 inhibition and increased FOXO3 acetylation [2],3\n- Continuous ketogenic diets induce tissue‑specific senescence, whereas intermittent ketosis avoids this toxicity [8]\n- Exogenous ketone esters achieve 1–7 mM ketosis for 0.5–6 h, offering a pulsatile HDAC inhibition window [9]\n- Circadian HDAC activity (e.g., HDAC3) gates clock‑controlled transcription; rhythmic HDAC inhibition can reinforce clock‑driven FOXO3 activation and antioxidant defenses\n\n## Novel Mechanistic Insight\n\nWe propose that intermittent BHB pulses synchronize the circadian HDAC3‑FOXO3 axis: during the early night, HDAC3 repression is lifted, allowing transient FOXO3 acetylation and SOD2/CAT induction; the subsequent HDAC activity rebound limits prolonged chromatin opening, thereby avoiding the SASP‑driven senescence seen with chronic HDAC blockade. This creates a ‘metabolic‑chronotherapeutic’ window where antioxidant output is maximized without triggering the p16^INK4a^/p21^Cip1^ senescence program.\n\n## Testable Predictions\n\n1. In human participants receiving intermittent BHB (ketone ester) dosing every 12 h, peripheral blood mononuclear cells will show a significant increase in acetyl‑FOXO3 and downstream SOD2/CAT expression peaking 2–4 h post‑dose, returning to baseline before the next dose.\n2. The same regimen will not elevate senescence markers (p16^INK4a^, p21^Cip1^, SASP cytokines IL‑6, IL‑8) compared with a continuous ketogenic diet control.\n3. Circadian transcriptomics will reveal enhanced amplitude of core clock genes (BMAL1, PER2) and HDAC3 expression rhythm, correlating with improved healthspan biomarkers (VO₂max, grip strength, cognitive processing speed).\n\n## Experimental Design\n\n- Population: 200 adults aged 60–80, randomized to three arms (n≈66 each): (A) intermittent ketone ester (0.5 g/kg BHB) every 12 h for 12 weeks; (B) isocaloric continuous ketogenic diet (70% fat) for 12 weeks; (C) standard diet control.\n- Intervention: Arm A receives ketone ester drink at 08:00 and 20:00; Arm B consumes ketogenic meals ad libitum; Arm C maintains habitual diet.\n- Readouts: baseline and every 4 weeks: plasma β‑hydroxybutyrate, acetyl‑FOXO3 (ChIP‑qPCR from PBMCs), SOD2/CAT mRNA, p16^INK4a^ protein (flow cytometry), SASP cytokine panel, VO₂max, grip strength, MoCA score, and 24‑h cortisol/melatonin to assess circadian phase.\n- Mechanistic substudy: subset (n=20 per arm) undergoes adipose tissue biopsy at ZT4 and ZT16 for HDAC3 activity assay and histone acetylation sequencing.\n\n## Potential Outcomes & Falsifiability\n\n- Supportive outcome: Arm A shows ↑ acetyl‑FOXO3 & antioxidant genes, no rise in senescence markers, improved VO₂max/grip strength, and heightened circadian amplitude vs. B and C.\n- Refuting outcome: Arm A exhibits comparable or increased senescence markers to Arm B, or fails to show pulsatile FOXO3 acetylation, indicating that intermittent BHB does not uncouple HDAC inhibition from senescence induction.\n\nThis hypothesis directly links dosing rhythm, circadian chromatin dynamics, and the balance between pro‑longevity FOXO3 signaling and senescence, providing a clear, falsifiable roadmap for the first large‑scale human trial of BHB as a longevity‑modulating HDAC inhibitor.